SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Critical Therapeutics (CRTX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates12/14/2005 8:57:01 AM
   of 31
 
On December 7, 2005, Critical Therapeutics, Inc. (the "Company") entered into an amendment to the Company's Exclusive License and Collaboration Agreement with MedImmune, Inc. ("MedImmune") dated July 30, 2003 (the "Collaboration Agreement"), related to the joint development of products directed toward HMGB1, or high mobility group box protein 1. Pursuant to the amendment, MedImmune has agreed to increase its funding of development support to the Company under the Collaboration Agreement by $1.0 million through the end of 2006. MedImmune had previously agreed to make a total of $3.0 million of development support payments to the Company through the end of 2006, of which $2.8 million had been billed to MedImmune through September 30, 2005...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News